Kinaset Therapeutics
Inhaled therapeutic molecules for severe asthma treatment
- Sector
- Biotech
- Headquarters
- MEDFIELD, MA
- Founded
- 2020
- Latest Form D
- $28.5M, Jul 2022
- Total capital
- $30M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $30M
- 2 Form D · last Jul 2022
- 51 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 8 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$28.5M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Bram VanparysDirectorNamed in SEC Form D filings
- Frazer MorganExecutive Officer, PromoterNamed in SEC Form D filings
- Jamil BegDirectorNamed in SEC Form D filings
- Kevin BittermanDirectorNamed in SEC Form D filings
- Robert ClarkeExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Roger HeermanExecutive Officer, PromoterNamed in SEC Form D filings
Show all 7 people
- Tom KingDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 8- PendingTreatment Of Copd Patient PopulationsUSPTOApplication 19286896
- PendingFormulation Of A Pan-jak InhibitorUSPTOApplication 18526352
- PendingFormulation Of A Pan-jak InhibitorUSPTOApplication PCTUS2023082047
Show all 8 patent records
- Treatment Of Copd Patient PopulationsFeb 5, 2026 · Application 19286896Pending
- Formulation Of A Pan-jak InhibitorAug 8, 2024 · Application 18526352Pending
- Formulation Of A Pan-jak InhibitorApplication PCTUS2023082047Pending
- Formulation Of A Pan-jak InhibitorApplication 63597934Pending
- Formulation Of A Pan-jak InhibitorApplication 63501086Pending
- Treatment Of Copd Patient PopulationsApplication PCTUS2025040050Pending
- Formulation Of A Pan-jak InhibitorApplication 63385847Pending
- Treatment Of Copd Patient PopulationsApplication 63677685Pending
Related companies, and why
- Intellia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Judo BioSimilar federal contract value in Biotech · null in contracts
- Furtim Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Korro BioSimilar federal contract value in Biotech · null in contracts
- Altis LabsSimilar federal contract value in Biotech · null in contracts
- Matchpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .